In 2023, Johnson & Johnson Innovative Medicine provided $42.8 billion in rebates, discounts and fees to insurers, pharmacy benefit managers (PBMs), hospitals, government programs and other healthcare entities. Despite these substantial concessions, the net prices for Johnson & Johnson’s medicines have declined by nearly 20% over the past seven years, yet many patients continue to face higher out-of-pocket costs and barriers to access.
All figures according to Johnson & Johnson internal financial accounting. Figures have been rounded.